Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 10
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C. Siripongboonsitti T, et al. Phytomedicine. 2023 Oct;119:155018. doi: 10.1016/j.phymed.2023.155018. Epub 2023 Aug 12. Phytomedicine. 2023. PMID: 37625206 Free article. Clinical Trial.
Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study).
Siripongboonsitti T, Ungtrakul T, Tawinprai K, Nimmol T, Buttakosa M, Sornsamdang G, Jarrusrojwuttikul T, Silapant P, Mahanonda N. Siripongboonsitti T, et al. Int J Infect Dis. 2023 Sep;134:211-219. doi: 10.1016/j.ijid.2023.06.018. Epub 2023 Jun 30. Int J Infect Dis. 2023. PMID: 37393041 Free article. Clinical Trial.
Pharmacokinetic Comparison of Favipiravir Oral Solution and Tablet Formulations in Healthy Thai Volunteers.
Siripongboonsitti T, Ungtrakul T, Watanapokasin N, Timsri P, Wongpakdee K, Wattanasin P, Pavitrapok C, Khunvichai A, Jamnongtanachot P, Mueannoom W, Kitpoka T, Arjharn W, Mahanonda N. Siripongboonsitti T, et al. Clin Pharmacol Drug Dev. 2023 Jan;12(1):14-20. doi: 10.1002/cpdd.1149. Epub 2022 Jul 25. Clin Pharmacol Drug Dev. 2023. PMID: 35877195 Clinical Trial.
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
Cohen G, Jungsomsri P, Sangwongwanich J, Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Cohen G, et al. Among authors: siripongboonsitti t. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24. Hum Vaccin Immunother. 2022. PMID: 35323079 Free PMC article.
Abnormality Pattern of F-18 FDG PET Whole Body with Functional MRI Brain in Post-Acute COVID-19.
Kiatkittikul P, Promteangtrong C, Kunawudhi A, Siripongsatian D, Siripongboonsitti T, Ruckpanich P, Thongdonpua S, Jantarato A, Piboonvorawong C, Fonghoi N, Chotipanich C. Kiatkittikul P, et al. Among authors: siripongboonsitti t. Nucl Med Mol Imaging. 2022 Feb;56(1):29-41. doi: 10.1007/s13139-021-00730-6. Epub 2022 Jan 15. Nucl Med Mol Imaging. 2022. PMID: 35069924 Free PMC article.
Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K, Jungsomsri P, Pinijnai O, Tavonvunchai F, Lievjaroen A, Suwannaroj P, Siripongboonsitti T, Porntharukchareon T, Sornsamdang G, Ungtrakul T. Tawinprai K, et al. Among authors: siripongboonsitti t. Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4. Hum Vaccin Immunother. 2023. PMID: 37140889 Free PMC article.
The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study.
Porntharukchareon T, Chartisathian W, Navinpipat M, Samdaengpan C, Cheirsilpa K, Lueprasitsakul A, Worawichawong S, Muangsillapasart V, Pumuthaivirat P, Dechates B, Sirisreetreerux S, Siripongboonsitti T, Rangsrisaeneepitak V, Jirawattanapalin K, Tawinprai K. Porntharukchareon T, et al. Among authors: siripongboonsitti t. Hum Vaccin Immunother. 2023 Aug 1;19(2):2251850. doi: 10.1080/21645515.2023.2251850. Hum Vaccin Immunother. 2023. PMID: 37671943 Free PMC article.
Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Wittayasak K, Thonwirak N, Soonklang K, Sornsamdang G, Auewarakul C, Mahanonda N. Tawinprai K, et al. Among authors: siripongboonsitti t. Expert Rev Vaccines. 2022 Dec;21(12):1873-1881. doi: 10.1080/14760584.2022.2099380. Epub 2022 Jul 13. Expert Rev Vaccines. 2022. PMID: 35792752 Clinical Trial.
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Dechates B, Monprach H, Sornsamdang G, Wittayasak K, Soonklang K, Mahanonda N. Tawinprai K, et al. Among authors: siripongboonsitti t. Hum Vaccin Immunother. 2022 Dec 31;18(1):2035573. doi: 10.1080/21645515.2022.2035573. Epub 2022 Mar 3. Hum Vaccin Immunother. 2022. PMID: 35240945 Free PMC article.
21 results